Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!

Biotech Battered To 2-Month Lows As Celgene Crashes

Courtesy of ZeroHedge. View original post here.

The S&P Biotech Index is now down 9% from its early October highs, extending losses today thanks to the collapse in Celgene's share price after it lowered its outlook.

As Bloomberg reports, Celgene Corp. dropped 18 percent in early U.S. trading after lowering its long-term profit target.

The drugmaker, known for its hematology and oncology treatments, is under pressure to refill its pipeline as its top-selling cancer treatment faces looming competition from generics. Last week, Celgene halted a final-stage trial of an experimental Crohn’s disease drug that analysts had anticipated could become a blockbuster, raising concerns that its 2020 profit guidance might be at risk.

On Thursday, the Summit, New Jersey-based company cut that long-term earnings guidance by 50 cents to $12.50 a share.

Which has slammed the Biotech Index lower…

Double top anyone?


Do you know someone who would benefit from this information? We can send your friend a strictly confidential, one-time email telling them about this information. Your privacy and your friend's privacy is your business... no spam! Click here and tell a friend!





You must be logged in to make a comment.
You can sign up for a membership or get a FREE Daily News membership or log in

Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!